PT - JOURNAL ARTICLE AU - Hernández-Terán, Alejandra AU - Mejía-Nepomuceno, Fidencio AU - Herrera, María Teresa AU - Barreto, Omar AU - García, Emma AU - Castillejos, Manuel AU - Boukadida, Celia AU - Matias-Florentino, Margarita AU - Rincón-Rubio, Alma AU - Avila-Rios, Santiago AU - Mújica-Sánchez, Mario AU - Serna-Muñoz, Ricardo AU - Becerril-Vargas, Eduardo AU - Guadarrama-Pérez, Cristobal AU - Ahumada-Topete, Víctor Hugo AU - Rodríguez, Sebastián AU - Martínez-Orozco, José Arturo AU - Salas-Hernández, Jorge AU - Pérez-Padilla, Rogelio AU - Vázquez-Pérez, Joel Armando TI - Dysbiosis and structural disruption of the respiratory microbiota in COVID-19 patients with severe and fatal outcomes AID - 10.1101/2021.05.19.21257485 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.19.21257485 4099 - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257485.short 4100 - http://medrxiv.org/content/early/2021/05/21/2021.05.19.21257485.full AB - COVID-19 outbreak has caused over 3 million deaths worldwide. Understanding disease pathology and the factors that drive severe and fatal clinical outcomes is of special relevance. Studying the role of the respiratory microbiota in COVID-19 is particularly important since it’s known that the respiratory microbiota interacts with the host immune system, contributing to clinical outcomes in chronic and acute respiratory diseases. Here, we characterized the microbiota in the respiratory tract of patients with mild, severe, or fatal COVID-19, and compared with healthy controls and patients with non-COVID-19-pneumonia. We comparatively studied the microbial composition, diversity, and microbiota structure across study groups and correlated the results with clinical data. We found differences in diversity and abundance of bacteria between groups, higher levels of dysbiosis in the respiratory microbiota of COVID-19 patients (regardless of severity level), differences in diversity structure among mild, severe, and fatal COVID-19, and the presence of specific bacteria that correlated with clinical variables associated with increased mortality risk. Our data suggest that host-related and environmental factors could be affecting the respiratory microbiota before SARS-CoV-2 infection, potentially compromising the immunological response of the host against disease and promoting secondary bacterial infections. For instance, the high levels of dysbiosis coupled with low microbial structural complexity in the respiratory microbiota of COVID-19 patients, possibly resulted from antibiotic uptake and comorbidities, could have consequences for the host and microbial community level. Altogether, our findings identify the respiratory microbiota as a potential factor associated with COVID-19 severity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThere were no clinical intervention nor drug administration during the present study, thus a registered trial was not neccesary.Funding StatementThis work was financially supported by Consejo Nacional de Ciencia y Tecnologia (CONACYT-FORDECYT 2020, grant "Caracterizacion de la diversidad viral y bacteriana" to JAVP) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Science, Biosecurity and Bioethics Committee of the Instituto Nacional de Enfermedades Respiratorias revised and approved the protocol and the consent procedure given by the participants or their legal guardians (B-0520). Additionally, the Institution requested an informed consent for the recovery, storage, and use of the biological remnant to research purposesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequencing reads generated during the present study are available in the NCBI Sequence Read Archive (SRA) accession PRNAJ726205.